Genetic variability of CYP2D6, CYP3A4 and CYP3A5 among the Egyptian population

被引:8
|
作者
Mutawi, Thuraya M. [1 ]
Zedan, Mohamed M. [2 ]
Yahya, Raida S. [1 ]
Zakria, Mahmoud M. [3 ]
El-Sawi, Mamdouh R. [4 ]
Gaedigk, Andrea [5 ,6 ]
机构
[1] Mansoura Univ, Children Hosp, Dept Labs, Fac Med, Mansoura 35516, Egypt
[2] Mansoura Univ, Dept Pediat, Fac Med, Mansoura 35516, Egypt
[3] Mansoura Univ, Urol & Nephrol Ctr, Fac Sci, Mansoura 35516, Egypt
[4] Mansoura Univ, Div Physiol, Dept Zool, Fac Sci, Mansoura 35516, Egypt
[5] Univ Missouri Kansas City, Childrens Mercy Kansas City, Div Clin Pharmacol Toxicol & Therapeut Innovat, Kansas City, MO 64108 USA
[6] Univ Missouri Kansas City, Sch Med, Kansas City, MO 64108 USA
关键词
genotype; phenotype Egyptian population; PHARMACOGENETICS IMPLEMENTATION CONSORTIUM; HUMAN CYTOCHROME-P450 2D6; POOR METABOLIZERS; CPIC GUIDELINE; CYP3A4-ASTERISK-22; POLYMORPHISMS; ALLELES; DUPLICATION; PHENOTYPE; VARIANTS;
D O I
10.2217/pgs-2020-0140
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aim: This study investigated major allelic variants of CYP2D6, CYP3A4 and CYP3A5 in Egyptians, an Arabic population for which there is little information regarding these important pharmacogenes. Patients & methods: CYP2D6*2, *4, *5, *10, *41 and gene copy number variation, as well as CYP3A4*22 and CYP3A5*3 were determined with commercially available TaqMan assays in 145 healthy study participants. Results: The CYP2D6 alleles identified suggest that the prevalence of poor metabolizers is low as none were found among the 145 subjects investigated. The frequency for CYP3A5 nonexpressers was 74.5% and the CYP3A4*22 allele frequency was low at 2.0%. Conclusion: These preliminary findings indicate that pharmacogene variation in Egyptians is different from those of other Middle Eastern/Arabic populations and warrants further investigation.
引用
收藏
页码:323 / 334
页数:12
相关论文
共 50 条
  • [21] Effect of CYP3A4 and CYP3A5 Genetic Polymorphisms on the Pharmacokinetics of Sirolimus in Healthy Chinese Volunteers
    Zhang, Jing
    Dai, Ying
    Liu, Zhihong
    Zhang, Minxin
    Li, Chen
    Chen, Dingxiong
    Song, Hongtao
    THERAPEUTIC DRUG MONITORING, 2017, 39 (04) : 406 - 411
  • [22] Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism
    Spitman, A. B. Sanchez
    Moes, D. J. A. R.
    Gelderblom, H.
    Dezentje, V. O.
    Swen, J. J.
    Guchelaar, H. J.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 73 (12) : 1589 - 1598
  • [23] Influence of CYP2D6 and CYP3A4 Phenotypes, Drug Interactions, and Vitamin D Status on Tamoxifen Biotransformation
    Antunes, Marina V.
    da Fontoura Timm, Tatiana Aparecida
    de Oliveira, Vanessa
    Staudt, Dilana E.
    Raymundo, Suziane
    Goessling, Gustavo
    Biazus, Jorge V.
    Cavalheiro, Jose A.
    Rosa, Daniela D.
    Wallemacq, Pierre
    Haufroid, Vincent
    Linden, Rafael
    Schwartsmann, Gilberto
    THERAPEUTIC DRUG MONITORING, 2015, 37 (06) : 733 - 744
  • [24] Metabolism of Quetiapine by CYP3A4 and CYP3A5 in Presence or Absence of Cytochrome B5
    Bakken, Gry Vibeke
    Rudberg, Ida
    Christensen, Hege
    Molden, Espen
    Refsum, Helge
    Hermann, Monica
    DRUG METABOLISM AND DISPOSITION, 2009, 37 (02) : 254 - 258
  • [25] Analysis of CYP3A4*1B and CYP3A5*3 polymorphisms in population of Bosnia and Herzegovina
    Semiz, Sabina
    Dujic, Tanja
    Ostanek, Barbara
    Prnjavorac, Besim
    Bego, Tamer
    Malenica, Maja
    Mlinar, Barbara
    Marc, Janja
    Causevic, Adlija
    MEDICINSKI GLASNIK, 2011, 8 (01) : 84 - 89
  • [26] Analysis of genetic variations in CYP2C9, CYP2C19, CYP2D6 and CYP3A5 genes using oligonucleotide microarray
    Dong, Yuanyuan
    Xiao, Huasheng
    Wang, Qi
    Zhang, Chunxiu
    Liu, Xiuming
    Yao, Na
    Sheng, Haihui
    Li, Haiyan
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (10): : 18917 - 18926
  • [27] The Respective Roles of CYP3A4 and CYP2D6 in the Metabolism of Pimozide to Established and Novel Metabolites
    Chapron, Brian D.
    Dinh, Jean C.
    Toren, Paul C.
    Gaedigk, Andrea
    Leeder, J. Steven
    DRUG METABOLISM AND DISPOSITION, 2020, 48 (11) : 1113 - 1120
  • [28] Study the polymorphism of CYP3A5 and CYP3A4 loci in Iranian population with laryngeal squamous cell carcinoma
    Negar Azarpira
    Mohamad Javad Ashraf
    Bigan Khademi
    Masumeh Darai
    Afsoon Hakimzadeh
    Elham Abedi
    Molecular Biology Reports, 2011, 38 : 5443 - 5448
  • [29] CYP3A4 and CYP3A5: the crucial roles in clinical drug metabolism and the significant implications of genetic polymorphisms
    Zhang, Yuqing
    Wang, Ziying
    Wang, Yuchao
    Jin, Weikai
    Zhang, Zheyan
    Jin, Lehao
    Qian, Jianchang
    Zheng, Long
    PEERJ, 2024, 12
  • [30] Regulation of CYP3A4 and CYP3A5 by a lncRNA: a potential underlying mechanism explaining the association between CYP3A4*1G and CYP3A metabolism
    Collins, Joseph M.
    Wang, Danxin
    PHARMACOGENETICS AND GENOMICS, 2022, 32 (01) : 16 - 23